Podrobno

Non-thermal ablation and drug delivery by electroporation : expanding current indications beyond cancer and cardiac treatment
ID Miklavčič, Damijan (Avtor), ID Cindrič, Helena (Avtor), ID Davalos, Rafael V. (Avtor), ID Deschamps, Frederic (Avtor), ID Gehl, Julie (Avtor), ID Kos, Bor (Avtor), ID Kramar, Peter (Avtor), ID Kuhelj, Dimitrij (Avtor), ID Meijerink, Martijn R. (Avtor), ID Soden, Declan M. (Avtor), ID Štabuc, Miha (Avtor), ID Serša, Gregor (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (1,42 MB)
MD5: 313C88C42234DB4B4C568696011E2207
URLURL - Izvorni URL, za dostop obiščite https://reference-global.com/article/10.2478/raon-2026-0040 Povezava se odpre v novem oknu

Izvleček
Background. Electroporation-Based Treatments and Therapies (EBTTs) – electrochemotherapy, irreversible electroporation, pulsed field ablation, and gene electro-transfer – use short, high-voltage electric pulses to permeabilize cell membranes, enabling non-thermal tissue ablation and enhanced local drug delivery. Although EBTTs have been used clinically for over three decades, primarily in oncology, their adoption remains limited compared to thermal ablation modalities. In contrast, cardiac pulsed field ablation (PFA) has seen rapid adoption since the first FDA device approval in December 2023. Conclusions. This expert opinion paper reviews the current clinical landscape of EBTTs in oncology and cardiac arrhythmia treatments, and focuses on emerging non-oncological and non-cardiac applications, including endoscopic pulsed electric field therapy for type 2 diabetes, bronchial rheoplasty for chronic bronchitis, bleomycin electrosclerotherapy for vascular malformations, nanosecond PFA for benign thyroid nodules, and electroporation-mediated gene delivery – and identifies key barriers to wider adoption: insufficient randomized evidence, lack of validated treatment planning tools, fragmented reimbursement, and limited standardization. We outline measures to facilitate clinical translation.

Jezik:Angleški jezik
Ključne besede:elektroporacija, ablacija s pulzirajočim poljem, elektrokemoterapija, ireverzibilna elektroporacije, genska elektrotransfekcija
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:FE - Fakulteta za elektrotehniko
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Založnik:Association of Radiology and Oncology
Leto izida:2026
Št. strani:str. 319-322
Številčenje:Vol. 60, no. 3
PID:20.500.12556/RUL-186665 Povezava se odpre v novem oknu
UDK:602.621
ISSN pri članku:1318-2099
DOI:10.2478/raon-2026-0040 Povezava se odpre v novem oknu
COBISS.SI-ID:287787523 Povezava se odpre v novem oknu
Datum objave v RUL:04.09.2026
Število ogledov:279
Število prenosov:70
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:electroporation, pulsed field ablation, electrochemotherapy, irreversible electroporation, gene electrotransfer

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj